FILING ANALYSIS · WEDNESDAY, NOVEMBER 4
Nuvation Bio Inc. NUVB — 8-K: Results of Operations and Financial Condition
neutral
Nuvation Bio reported $45 million in Q3 revenue, with $27.5 million from IBTROZI sales, and received FDA approval for a label update and Fast Track Designation for safusidenib, but no significant quantified surprise was disclosed.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →